MENU
AGEN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Agenus (AGEN) Ownership - Who owns Agenus?
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
3 Forbes Road
Phone
+1 781 674-4400
Employees
389
Web
https://www.agenusbio.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
113.23M
P/E Ratio
0.14
Total Cash
44.78M
Projected Growth
N/A
Total Debt
78.39M
Revenue
160.43M
Risk (Beta)
1.58
Dividend Yield
N/A
Total Cash/Share
1.63
Total Debt/Equity
14.79
Revenue/Share
4.62 USD as % of share price
Fundamentals
AGEN
Capitalization
113M
P/E Ratio
0.14
Risk (Beta)
1.58
Dividend Yield
N/A
Total Cash
44.8M
Total Cash/Share
1.63
Total Debt
78.4M
Total Debt/Equity
14.79
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
4.62%
Revenue
160M
ROE
N/A
Book Value
-292.34M
P/B Ratio
N/A
Cash Flow
N/A
Earnings
-11.02
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
217K
Current Ratio
0.19
Current Revenue Per Employee
64555.27
Dividends Per Share - Security
N/A
EBITDA
-77.64M
Float
N/A
Float - Current
N/A
Gross Income Margin
-64.08
Revenue To Assets
-79.40
Shares Held By Institutions
32.5M
Shares Outstanding - Current
27.4M
Total Liabilities
510M
Total Volume MTD
N/A
Value
-1
Gain YTD
50.730
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a developer of technologies to treat cancers and infectious diseases
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
3 Forbes Road
Phone
+1 781 674-4400
Employees
389
Web
https://www.agenusbio.com